This pilot study will collect preliminary data that measures the effects of psychedelic-assisted psychotherapy on patients struggling with alcohol use.
Status: Not yet recruiting
Start date: 2022-08-01
Phase II
Open
20 participants
Interventional
The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD).
Status: Not yet recruiting
Start date: 2022-10-10
Phase II
Blinded
90 participants
Interventional
This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM-120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).
Status: Recruiting
Start date: 2022-06-27
Phase II
Blinded
200 participants
Interventional
This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
Status: Not yet recruiting
Start date: 2022-10-01
Blinded
100 participants
Interventional
The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose psilocybin 1mg) in the treatment of anxiety, depression, and existential distress in advanced cancer.
Status: Not yet recruiting
Start date: 2022-11-01
Phase II
Blinded
300 participants
Interventional
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
Status: Not yet recruiting
Start date: 2022-09-01
Phase II
Open
10 participants
Interventional
This double-blind randomized-controlled trial will assess the effects of two small doses of synthetic psilocybin in capsule form each week for six weeks in people with depression.
Status: Planned
Start date: 2022-11-01
Phase II
Blinded
266 participants
Interventional
This study will investigate the effects of KR-101 (a psilocybin-based medicine) in participants with cancer-related distress.
Status: Planned
Phase II
Open
Interventional
In this study, we will complete a randomised controlled trial to test a 7 week (2 dose) psilocybin-assisted psychotherapy for the treatment of GAD. 72 individuals will be randomly assigned to receive two doses either psilocybin (25mg or 30mg, oral) or placebo (diphenhydramine, 75mg or 100mg, oral) with three weeks between doses.
Status: Recruiting
Start date: 2022-01-10
Phase II
Blinded
70 participants
Interventional
A Study of a Psilocybin Analog (CYB003) in Participants With Major Depressive Disorder
Status: Not yet recruiting
Start date: 2022-07-19
Phase I
Blinded
40 participants
Interventional
The primary objective of the study is to determine the reduction in anxiety symptoms for up to twelve weeks after a single administration of MM-120, compared across five treatment arms.
Status: Planned
Phase II
Blinded
200 participants
Interventional
To study the effects of MDMA, compared to a prototypical stimulant, on social motivation, social ability, and neural indices of social function in healthy volunteers.
Status: Recruiting
Start date: 2022-05-01
Phase I
Blinded
36 participants
Interventional
e main goal is to compare the antidepressant effects of psilocybin and ketamine in patients with TRD versus the antidepressant inactive substance midazolam.
Status: Recruiting
Start date: 2021-05-01
Phase II
Open
60 participants
Interventional
The present study is a modern randomized cross-over trial, investigating different continuous intravenous DMT dose rates over a broad dose range.
Status: Not yet recruiting
Start date: 2022-09-01
Phase I
Blinded
24 participants
Interventional
This open-label fMRI study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with treatment-resistant major depressive disorder.
Status: Not yet recruiting
Start date: 2022-06-01
Phase II
Open
20 participants
Interventional
This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD.
Status: Not yet recruiting
Start date: 2022-11-01
Phase I
Blinded
30 participants
Interventional
LSD has been reported to abort attacks, decrease the frequency and intensity of attacks, and induce remission in patients suffering from cluster headaches (CH).
Status: Recruiting
Start date: 2019-01-02
Phase II
Blinded
30 participants
Interventional
The double-blind, randomised, placebo-controlled study (“PSILAUT”) will investigate whether there is a difference in the function of serotonin brain networks in autistic and non-autistic adults.
Status: Planned
Phase II
Blinded
70 participants
Interventional
The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia.
Status: Completed
Start date: 2021-04-26
Phase II
Open
37 participants
Interventional
This Phase II trial with 18 participants will investigate the safety and feasibility of using MDMA-AT for eating disorders (anorexia nervosa & binge eating disorder).
Status: Not yet recruiting
Start date: 2020-07-01
Phase II
Open
12 participants
Interventional
The study will evaluate the safety, tolerability and PK profile of BPL-003 (5-MeO-DMT) in healthy subjects.
Status: Recruiting
Start date: 2022-02-14
Phase I
Blinded
56 participants
Interventional
The primary objective is to evaluate the effect of MDMA-assisted psychotherapy for MDD in clinician-rated depression scores, as measured by the mean change in MADRS scores from Visit 4 (Baseline) to Visit 13 (approximately 12 weeks post Baseline).
Status: Recruiting
Phase II
Open
12 participants
Interventional
The purpose of this research study is to investigate the safety and feasibility of two oral doses of psilocybin when combined with behavioural support for methamphetamine use disorder (MUD).
Status: Planned
Start date: 2022-04-18
Phase I
Open
12 participants
Interventional
To compare the physiological and psychological effects of psilocin taken orally by pill or sublingually by dissolving a tablet under the tongue to those of psilocybin taken by pill in healthy adults.
Status: Recruiting
Start date: 2022-07-04
Phase I
Blinded
20 participants
Interventional
The safety and tolerability of COMP360 in participants with post-traumatic stress disorder (PTSD).
Status: Recruiting
Start date: 2022-04-11
Phase II
Open
29 participants
Interventional
This study will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).
Status: Not yet recruiting
Start date: 2022-04-18
Phase I
Open
20 participants
Interventional
To better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP 8802 (psilocybin) among individuals with Binge Eating Disorder.
Status: Not yet recruiting
Start date: 2022-10-03
Open
10 participants
Interventional
The present study compares acute responses to R-MDMA, S-MDMA, MDMA, and placebo in a cross-over study in healthy subjects.
Status: Not yet recruiting
Start date: 2022-06-30
Phase I
Blinded
24 participants
Interventional
The long-term objective of this project is to characterize how psilocybin affects visual perception and the brain's representation of the visual environment.
Status: Not yet recruiting
Start date: 2022-05-01
Phase I
Blinded
80 participants
Interventional
The purpose of this trial is to examine the safety and efficacy of small (2mg) sub hallucinogenic doses of psilocybin in people with Persistent Depressive Disorder.
Status: Not yet recruiting
Start date: 2022-04-04
Phase II
Blinded
50 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
